Indoco Remedies · NSE: INDOCO · BSE: 532612
Q3 FY22 results · Oct–Dec 2021
Indoco Remedies reported revenue from operations of ₹358.00 crore (up 7.7% from Q3 FY21) and net profit of ₹32.99 crore (up 30.1% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 358.00 | 332.29 | +7.7% | 386.87 | −7.5% |
| Other income | 0.16 | 0.36 | −55.6% | 1.01 | −84.2% |
| Total income | 358.16 | 332.65 | +7.7% | 387.88 | −7.7% |
| Profit before tax | 50.58 | 37.63 | +34.4% | 64.95 | −22.1% |
| Net profit for the period | 32.99 | 25.36 | +30.1% | 41.69 | −20.9% |
| EPS, basic (₹) | 3.58 | 2.75 | +30.2% | 4.52 | −20.8% |
| Net margin (%) | 9.2 | 7.6 | 10.8 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 357.76 | 331.94 | +7.8% | 386.59 | −7.5% |
| Other income | 0.16 | 0.37 | −56.8% | 1.01 | −84.2% |
| Total income | 357.92 | 332.31 | +7.7% | 387.60 | −7.7% |
| Profit before tax | 50.53 | 37.42 | +35.0% | 64.81 | −22.0% |
| Net profit for the period | 32.97 | 25.14 | +31.1% | 41.57 | −20.7% |
| EPS, basic (₹) | 3.58 | 2.73 | +31.1% | 4.51 | −20.6% |
| Net margin (%) | 9.2 | 7.6 | 10.8 |
Consolidated
- Filed with BSE
- 01 Feb 2022, 15:04 IST
- Board meeting
- 01 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Feb 2022, 15:04 IST
- Board meeting
- 01 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE